Cargando…

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages

Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive environment. Within the TME, tumor-associated cells (TA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehlers, Femke A. I., Mahaweni, Niken M., van de Waterweg Berends, Annet, Saya, Thara, Bos, Gerard M. J., Wieten, Lotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198883/ https://www.ncbi.nlm.nih.gov/pubmed/36656341 http://dx.doi.org/10.1007/s00262-022-03365-4

Ejemplares similares

Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
por: Sarkar, Subhashis, et al.
Publicado: (2013)

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity
por: Gong, Ying, et al.
Publicado: (2021)

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
por: Beelen, Nicky A., et al.
Publicado: (2022)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors
por: Van Elssen, Catharina, et al.
Publicado: (2020)

Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
por: van Gelder, Michel, et al.
Publicado: (2016)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Polymorphic differences within HLA‐C alleles contribute to alternatively spliced transcripts lacking exon 5
por: Ehlers, Femke A. I., et al.
Publicado: (2022)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation
por: Duygu, Burcu, et al.
Publicado: (2021)

NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27
por: Dondero, Alessandra, et al.
Publicado: (2017)

IL-2–dependent adaptive control of NK cell homeostasis
por: Gasteiger, Georg, et al.
Publicado: (2013)

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
por: Woo, Jacky, et al.
Publicado: (2013)

Viral Infection of Human Lung Macrophages Increases PDL1 Expression via IFNβ
por: Staples, Karl J., et al.
Publicado: (2015)

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
por: Sarkar, Subhashis, et al.
Publicado: (2015)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial
por: van Gorkom, Gwendolyn N. Y., et al.
Publicado: (2022)

Sex-Associated Expression of Co-Stimulatory Molecules CD80, CD86, and Accessory Molecules, PDL-1, PDL-2 and MHC-II, in F480+ Macrophages during Murine Cysticercosis
por: Togno-Peirce, Cristián, et al.
Publicado: (2013)

IL-10 Is Critically Involved in Mycobacterial HSP70 Induced Suppression of Proteoglycan-Induced Arthritis
por: Wieten, Lotte, et al.
Publicado: (2009)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

The PDL1-inducible GTPase Arl4d controls T effector function by limiting IL-2 production
por: Tolksdorf, Felix, et al.
Publicado: (2018)

Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Tete, Sarah M., et al.
Publicado: (2014)

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
por: Fernandez, Rafael Alonso, et al.
Publicado: (2022)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR
por: Purcell, James W., et al.
Publicado: (2014)

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7onnd99qd796s4vuirbi53i6q